Where results make sense

About us   |   Why use us?   |   Reviews   |   PR   |   Contact us

[No title]   (Site not responding. Last check: 2007-10-11) Biosyn, Inc., is a drug research and development company in Philadelphia focusing on novel, targeted-delivery therapies for the prevention and treatment of infectious disease, with a positioning in markets where significant medical needs exist. Biosyn's leading product is a topical microbicide called SAVVY(R), designed to prevent the transmission of HIV and AIDS and is presently being investigated for safety and efficacy in late Phase I clinical trials at the University of Pennsylvania, University of Pittsburgh, and Eastern Virginia Medical Schools. Biosyn is a drug research and development company focused on novel, targeted-delivery therapies for the treatment and prevention of infectious disease. www.acor.org /drugs/pipeline/news/parsed/5547804.news   (525 words)

Press Release   (Site not responding. Last check: 2007-10-11) Biosyn’s lead product candidate, 1.0% C31G vaginal gel is in development for contraception and prevention of sexually transmitted diseases (STDs) including HIV, chlamydia and herpes. Biosyn is a specialty pharmaceutical company focused on the development and commercialization of novel drugs in the areas of infectious disease and reproductive health. Biosyn’s product portfolio offers significant competitive advantages in areas where there is a critical need for new or alternative therapies. www.biosyn-inc.com /PR10022003.html   (429 words)

Appendix A - General Computer Information Biosyn will not disclose the types of vegetation (a team of paleobotanists is still working on that), but Biosyn's exhibit specialists want a combination of swamp and savanna, both of which have low vegetation and will thus enhance viewing. A Biosyn ecologist you have met with privately concedes that a substantial amount of forest will be needed as a food source and refuge. Biosyn ecologists estimate this will mean a population of at least 20. www.marietta.edu /~mcshaffd/eco/sym/EKAPG98.html   (984 words)

RoboDesign News and Events   (Site not responding. Last check: 2007-10-11) Over the years, biosyn has developed and perfected non-lethal techniques for handling Giant Keyhole limpet for the extraction of Hemolymph-sera, ensuring an environmentally friendly process for the development and manufacture of the life saving drugs from the sea. biosyn Corporation, a wholly owned subsidiary of biosyn, Germany, is a biopharmaceutical company focused on the development, manufacturing and marketing of novel Hemocyanin and Immunocyanin products as cancer therapeutics, immune stimulators and carrier proteins. biosyn is also involved in the manufacture and marketing of generic and brand name pharmaceutical drugs and trace elements and food supplements in the field of oncology. www.robodesign.com /pr_2002_03_26.shtml   (606 words)

AEGiS-PRn: Biosyn, Inc. Obtains Exclusive Rights to Novel HIV Microbicide Candidate from National Institutes of Health Based on these data, Biosyn foresees significant potential in the development of CV-N as a microbicide to prevent the sexual transmission of HIV. Under the NIH license, Biosyn receives exclusive, worldwide rights to the development and commercialization of CV-N as a microbicide, in exchange for certain milestone and royalty payments to be made to the NIH. Biosyn's lead product candidate, 1.0% C31G vaginal gel (Savvy(R)) is entering Phase III clinical trials in 2003 for contraception and the prevention of transmission of STDs. www.aegis.com /news/PR/2003/PR030410.html   (709 words)

TheDeal.com - Cellegy buys Biosyn for $30M Biosyn president and CEO Anne-Marie Corner will stay with Cellegy and lead the Biosyn team in its current Huntingdon Valley, Pa., location. Biosyn suggests the gel may also protect the user against other sexually transmitted diseases. Biosyn has received about $50 million in grants and contract commitments from several organizations, including the United States Agency for International Aid and the International Partnership for Microbicides. www.thedeal.com /NASApp/cs/ContentServer?pagename=TheDeal/TDDArticle/StandardArticle&c=TDDArticle&cid=1097185495767&r=InFs&p=M4YD5AR2   (437 words)

Kemestrie Inc. - Fluid-bed reactor gasification for recovery of energy from organic residues (Biosyn) - transforming ...   (Site not responding. Last check: 2007-10-11) The Biosyn process, developed by Kemestrie Inc. and its partners, offers an energy efficiency exceeding that of conventional combustion or pyrolysis processes by approximately 50%, with a reduction in atmospheric emissions and the volume of waste to be buried. The variables determining the energy performance of the Biosyn process are the composition and calorific content of the raw material, its humidity and its inorganic inert matter content. In addition to the Biosyn pilot unit in operation at the Université de Sherbrooke, a demonstration unit is located at the Alcan research centre in Arvida (Quebec). www.enviroaccess.ca /fiches_4/F4-11-96a.html   (1086 words)

The Pennsylvania Gazette Jul/Aug: Gazetteer   (Site not responding. Last check: 2007-10-11) As part of a research group, Biosyn has developed a vaginal gel that would prevent pregnancy and protect both partners against a variety of STDs, including AIDS, syphillis, herpes and now–if SDS is added to the mix–HPV. Biosyn originally had developed a compound that was both spermicidal and effective against a large variety of bacteria and viruses that cause STDs. Using funding from the National Institutes of Health, researchers at Biosyn, Penn State’s Milton S. Hershey Medical Center and other institutions searched for a compatible agent that could be combined with the existing formulation to fight human papillomaviruses. www.upenn.edu /gazette/0799/0799gaz2.html   (542 words)

Nominet:DRS 02822 agera   (Site not responding. Last check: 2007-10-11) Biosyn granted the Complainant an exclusive, non-transferable and royalty free licence to use its trademarks, logos and trade names, and all derivatives thereof, including Agera and AgeraRx. The Respondent recognises that the Complainant is the appointed distributor of Biosyn Agera and AgeraRx products in the UK and that those products are beneficial to the day-to-day skin care of their patients and are an important therapeutic vehicle to complement other treatment modalities offered by the Respondent. The Complainant was granted an exclusive licence to use Biosyn’s trademarks for the purposes of marketing and promotion, distribution and sale of Biosyn’s products in the UK, which also predates the registration of the Domain Name, and that licence remains in force. www.nic.uk /DisputeResolution/Decisions/Drs02822Agera.html   (2950 words)

PABIOTIECH - Member Profile   (Site not responding. Last check: 2007-10-11) The company is developing product candidates based upon four core technologies for several key market segments including: 1) the treatment and prevention of Sexually Transmitted Diseases (STDs) 2) the treatment and prevention of Oral Infections associated with Immuno-suppression and 3) the treatment and prevention of Skin and Soft Tissue Infections (SSTIs) including acne and impetigo. In the area of HIV and STD prevention, Biosyn has become a leader in the development of microbicides, intra-vaginal gels to prevent or reduce transmission of STDs. The company’s lead compound, 1.0% C31G vaginal gel (Savvy®), has recently completed Phase I/II safety and efficacy studies successfully and is positioned to enter Phase II/III clinical trials for the prevention of STDs including chlamydia, herpes simplex virus (HSV), human immunodeficiency virus (HIV) as well as contraception. www.pabiotech.org /cgi-bin/mdirectory_view.cgi?2&57   (207 words)

Microbicides as an Alternative Solution: [Press release from Biosyn/Cromptom]   (Site not responding. Last check: 2007-10-11) Crompton Corporation (NYSE:CK) and Biosyn, Inc. today announced the signing of a worldwide exclusive licensing agreement for Biosyn to develop Crompton's UC 781 compound as a topical microbicide targeted against the AIDS virus. Crompton scientists, in consultation with world-renowned experts at the Rega Institute in Belgium and McGill University in Canada, have optimized UC 781 for the treatment of patients with HIV/AIDS and for the prevention of transmission of the virus to the uninfected. Biosyn is a research and development company focused on the development of novel, targeted delivery drugs for the treatment and prevention of infectious disease. www.microbicidesnow.org /news/010523.php   (681 words)

Healthcare Sales & Marketing Network News: Biosyn, Inc. Initiates Phase 3 Pivotal Clinical Trial with 1% C31G Vaginal ... All study participants are counseled on safe sex practices and are strongly encouraged to use condoms that are provided during the trial. Biosyn expects to conduct a second parallel Phase 3 study, in Nigeria, in the near future. Phase 3 contraceptive efficacy trials are expected to commence shortly in the United States, and other trials looking at the effects on herpes and chlamydia are planned. salesandmarketingnetwork.com /news_release.php?ID=15795   (662 words)

[No title] Biosyn's strategy is to build a portfolio of microbicide candidates that have different modes of action, and UC781 is clearly the best NNRTI for this application. Terms of the Transaction In exchange for worldwide exclusive rights for topical microbicide applications, Biosyn will fund all development costs and give Crompton milestone and royalty payments, including exercisability of warrants if Phase III trials are initiated for HIV claims on a UC781 product. About Biosyn Biosyn is a research and development company focused on the development of novel, targeted delivery drugs for the treatment and prevention of infectious disease. www.microbicidesnow.org /news/010523.txt   (483 words)

Cellegy: Newsroom   (Site not responding. Last check: 2007-10-11) Biosyn's Savvy product is the clinical leader in the competition to develop a contraceptive gel that also prevents HIV transmission to women. In women's healthcare, Cellegy is developing Tostrelle for the treatment of sexual dysfunction (libido) in postmenopausal women and is planning to enter Phase 3 clinical trials during the first half of 2005. Savvy is in separate Phase 3 clinical trials for contraception and for the prevention of HIV. www.cellegy.com /newsroom/press/10nov04.html   (1416 words)

THE MOST RECENT ADVANCE IN SKINCARE   (Site not responding. Last check: 2007-10-11) Biosyn Inc. offers MagC as a component for topical applications in various delivery systems specifically designed for the enhancement of collagen elastin, and proteoglucan formation. Biosyn has chosen to include a peptide pigmentation inhibitor in many of its MagC products. Biosyn has combined MagC with a peptide tyrosinase to enhance the inhibitory pigmentation effects. www.agera.com /highdose.htm   (719 words)

The Body: California; Pennsylvania: Montco Firm Working to Prevent HIV Is Sold Since then, Biosyn secured $50 million in grants and $18 million in investment to get Savvy, its microbicide gel, into late-stage clinical tests. With the deal, Biosyn acquires a product that is in two Phase III clinical trials in Africa for preventing sexual transmission of HIV. In contrast, the Biosyn product could be on the market by the end of 2007, the companies said. www.thebody.com /cdc/news_updates_archive/2004/oct11_04/cellegy.html   (409 words)

Knowledge Express® The net loss for the year ended December 31, 2004 was $28.2 million or $1.28 per share based on 22,021,000 weighted average shares outstanding, compared with the 2003 net loss of $13.5 million or $0.68 per share based on 19,964,000 weighted average shares outstanding. Biosyn grant revenue of $1,005,000 for the October 22nd to December 31, 2004 period was primarily related to grant funding from several government and philanthropic agencies in support of its HIV/AIDs development programs. These were offset somewhat by research and development expenses of $800,000 incurred by Biosyn for the period from October 22nd to December 31, 2004 and other Cellegy research expenditures of $541,000 in 2004. www.knowledgeexpress.com /local/detail.asp?id=196323&source=DMSNews   (964 words)

Cellegy: Newsroom   (Site not responding. Last check: 2007-10-11) Cellegy's Biosyn subsidiary is conducting two Phase 3 HIV prevention trials in Africa (Ghana and Nigeria). The addition of Biosyn, a leader in the development of novel microbicide gel products for contraception and the prevention of HIV in women, expands Cellegy's near term product pipeline and complements Cellegy's women's health focus. Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including sexual dysfunction and HIV prevention, gastrointestinal disorders and certain cancers. www.cellegy.com /newsroom/press/03mar05.html   (715 words)

FDA Grants Fast Track Designation for 1.0% C31G Vaginal Gel for Reduction of HIV Transmission   (Site not responding. Last check: 2007-10-11) HUNTINGDON VALLEY, PA -- November 17, 2003 -- Biosyn, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development program of 1.0% C31G vaginal gel for the reduction of HIV transmission. In granting the Fast Track designation, the FDA recognized that HIV infection is a serious and life-threatening condition, there is an unmet need for a female controlled method to reduce the sexual transmission of HIV and 1.0% C31G has the potential to address this unmet medical need. Biosyn's lead product candidate, 1.0% C31G vaginal gel is entering Phase III clinical trials. www.docguide.com /dg.nsf/PrintPrint/615F15E7789660E685256DE100506632   (402 words)

The Body: FDA Fast Tracks Biosyn Gel Product Biosyn Inc. of Huntingdon Valley, Pa., announced Monday that the Food and Drug Administration had granted "fast track" designation to its C31G vaginal gel designed to reduce HIV transmission. Fast track programs facilitate the development and expedite the review of new drug candidates intended to prevent or treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Biosyn's gel is entering phase III clinical trials for prevention of HIV transmission, prevention of chlamydia and contraception. www.thebody.com /cdc/news_updates_archive/2003/nov19_03/biosyn_gel.html   (204 words)

XBiz - Clinical Trial Underway for HIV Prevention Gel Biosyn's 1% C31G Vaginal Gel is expected to help reduce the sexual transmission of HIV in addition to sexually transmitted infections like chlamydia and herpes. According to Biosyn's statistics, the United States has the highest rates of sexually transmitted infections than any other country in the industrialized world. Biosyn will also conduct the same testing process in Nigeria at a yet-undetermined time. xbiz.com /news_piece.php?id=3468   (723 words)

Globeinvestor.com: Cellegy Announces First Quarter 2005 Results The increase includes $417,000 of Biosyn expenses that were not included in the prior year. The remaining increase of $2,196,000 was primarily attributable to increases of $1,479,000 in legal and professional fees, $428,000 in salaries expense and $289,000 write-off of fixed assets. The addition of Biosyn, a leader in the development of novel microbicide gel products for contraception and the reduction in transmission of HIV in women, expands Cellegy's near term product pipeline and complements Cellegy's women's health care focus. www.globeinvestor.com /servlet/WireFeedRedirect?cf=GlobeInvestor/config&vg=BigAdVariableGenerator&date=20050516&archive=prnews&slug=2005_05_16_07_4229_1370822   (1600 words)

PR Newswire: Biosyn, Inc. Initiates Phase I Clinical Testing of UC-781, a Novel HIV Microbicide.@ HighBeam Research   (Site not responding. Last check: 2007-10-11) Biosyn, Inc. Initiates Phase I Clinical Testing of UC-781, a Novel HIV Microbicide. HUNTINGDON VALLEY, Pa., Sept. 4 /PRNewswire/ -- Biosyn, Inc. announced today that enrollment has been initiated for a Phase I clinical trial for the investigational drug candidate, UC-781, as a microbicide for the prevention of sexually transmitted HIV. UC-781 is an HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) that has shown in vitro to be very active specifically against HIV-1. www.highbeam.com /library/doc0.asp?DOCID=1G1:107234093&refid=holomed_1   (219 words)

AEGiS-PRn: Biosyn, Inc. Receives up to $10 Million for the Development of a Novel HIV Fusion Inhibitor AEGiS-PRn: Biosyn, Inc. Receives up to $10 Million for the Development of a Novel HIV Fusion Inhibitor HUNTINGDON VALLEY, Pa., Oct. 2 /PRNewswire/ -- Biosyn, Inc. announced today that the International Partnership for Microbicides (IPM) has agreed to provide up to $10 million in milestone-driven funding over the next four years for the advancement of cyanovirin-N (CV-N), a novel fusion inhibitor in development for the prevention of transmission of HIV. Other products in clinical development at Biosyn include UC-781, a non- nucleoside reverse transcriptase inhibitor in Phase I trials for the prevention of HIV transmission, and 0.5% C31G oral rinse, entering Phase II trials for management of oral infections associated with immune-suppression. www.aegis.com /news/pr/2003/PR031005.html   (656 words)

LT Biosyn LT Biosyn, Inc. specializes in the manufacture, R and D and marketing of plant growth regulators. Several of LT Biosyn’s technical products are registered with the USEPA, such as 6BA, GA3, GA4+7, IBA, and Kinetin. • LT Biosyn, Inc. (U.S.A) has an alliance with the Taiwan based company, Lysine Biotech Inc. LT Biosyn, Inc. is primarily responsible for management, R and D and marketing activities in NAFTA countries, Europe and Central Latin America countries, while Lysine Biotech Inc. focuses on manufacturing, supply and marketing in the Far East countries. www.ltbiosyn.com   (200 words)

Cellegy Pharmaceuticals Reports 2004 Financial Results About Cellegy Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including reduction in the transmission of HIV and sexual dysfunction, gastrointestinal disorders and certain cancers. The addition of Biosyn, a leader in the development of novel microbicide gel products for contraception and the reduction in transmission of HIV in women, expands Cellegy's near term product pipeline and complements Cellegy's women's health focus. Purchased research and development expense of $14,982,000 was incurred during 2004, representing the write off of the allocated fair value of the purchased research and development of Biosyn when the acquisition was completed in October 2004. www.prnewswire.com /cgi-bin/stories.pl?ACCT=109&STORY=/www/story/03-29-2005/0003288321&EDATE=   (1869 words)

The Jurassic Tales: Members But after Kurtis Turner finds BioSyn is working on a Jurassic Park of their own, he calls Dan Ben. Jurassic Park 3: Jurassic World - Henry Wu is in need of a job when he meets a mysterious man dressed in a fl trenchcoat with sundglasses in the middle of the night. Silence - Laura is sent to Isla Nublar on a inspection to test the stability of the park, when chaos breaks loose. www.geocities.com /Hollywood/Lot/6851/6.htm   (1524 words)

Try your search on: Qwika (all wikis)

About us   |   Why use us?   |   Reviews   |   Press   |   Contact us   Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.